NeurAxis-IB-Sutiデバイスで10代のIBSを治療し,5100万人がMolina健康ケアメンバーを対象としている. NeurAxis' IB-Stim device for treating IBS in teens gains coverage for 5.1 million Molina Healthcare members.

医療技術企業であるNeurAxisは,13州で約510万人の会員を対象とした,Molina Healthcareとの間でIB-Stimデバイスの保険を保証しました. NeurAxis, a medical tech company, has secured insurance coverage for its IB-Stim device with Molina Healthcare, covering about 5.1 million members across 13 states. 刺激性腸症候群 (IBS) を患っている8~21歳の青少年における機能性腹痛の治療にFDAが承認したIB-Stimは,耳にある頭蓋骨神経に軽い電気インパルスを送る非手術装置です. IB-Stim, FDA-cleared for treating functional abdominal pain in adolescents aged 8-21 with irritable bowel syndrome (IBS), is a non-surgical device that delivers gentle electrical impulses to cranial nerves in the ear. この保険の拡大は,IB-Stimの保険の大幅な増加に続いており,現在,5100万人の生命をカバーしています. This coverage expansion follows a significant increase in insurance coverage for IB-Stim, now reaching 51 million lives.